Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Total Non-Current Liabilities: 2021-2024

Historic Total Non-Current Liabilities for Autolus Therapeutics (AUTL) over the last 4 years, with Dec 2024 value amounting to $355.0 million.

  • Autolus Therapeutics' Total Non-Current Liabilities rose 13.12% to $396.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $396.0 million, marking a year-over-year increase of 13.12%. This contributed to the annual value of $355.0 million for FY2024, which is 34.69% up from last year.
  • As of FY2024, Autolus Therapeutics' Total Non-Current Liabilities stood at $355.0 million, which was up 34.69% from $263.6 million recorded in FY2023.
  • In the past 5 years, Autolus Therapeutics' Total Non-Current Liabilities ranged from a high of $355.0 million in FY2024 and a low of $92.1 million during FY2021.
  • In the last 3 years, Autolus Therapeutics' Total Non-Current Liabilities had a median value of $263.6 million in 2023 and averaged $270.0 million.
  • Data for Autolus Therapeutics' Total Non-Current Liabilities shows a peak YoY skyrocketed of 107.88% (in 2022) over the last 5 years.
  • Yearly analysis of 4 years shows Autolus Therapeutics' Total Non-Current Liabilities stood at $92.1 million in 2021, then skyrocketed by 107.88% to $191.5 million in 2022, then surged by 37.64% to $263.6 million in 2023, then surged by 34.69% to $355.0 million in 2024.